Monomorphic post-transplant lymphoproliferative disorder with plasmablastic differentiation: a challenge for diagnosis and treatment
Authors: Jinjun Cheng, MD PhD1,3,4*, Sarah Harney, MD2, Keri Toner, MD2,3,4, Paige Kube, MD2, Metin Ozdemirli, MD5, Birte Wistinghausen, MD 2,3,4*
1. Department of Pathology and Laboratory Medicine, Children’s National Hospital, Washington, DC
2. Center for Cancer and Blood Disorders. Children’s National Hospital, Washington, DC
3. Center for Cancer and Immunology Research, Children’s National Hospital, Washington, DC
4.The George Washington University School of Medicine and Health Sciences, Washington, DC.
5. Department of Pathology, MedStar Georgetown University Hospital, Washington, DC.
*Correspondence to:
Jinjun Cheng, MD, PhD
Pathology and Laboratory Medicine Division
Children’s National Hospital
Room 1629, 111 Michigan Avenue NW
Washington, DC 20010-2970
Telephone: 202-476-4311
Fax: 202-476-4030
Email: jcheng2@childrensnational.org
Birte Wistinghausen, MD
Center for Cancer and Blood Disorders
Children’s National Hospital
111 Michigan Ave NW
Washington, DC 20010
Tel: 202-476-2800
Fax: 202-476-5685
Email: bwistingha@childrensnational.org
Word Count: 1200
Abstract count : 64
Tables: 1
Figures: 1
Running title: Pediatric post-transplant plasmablastic lymphoma
Key words: PTLD, Rituximab, EBV, PBL, DLBCL, PEL